Health authority remains committed to its use as second case of blood clot from AstraZeneca vaccine reported in Canada

Toronto, Canada, April 18 2021:  The Canadian health authority says the country has recorded a second case of rare but serious blood clotting linked to AstraZeneca’s Covid-19 vaccine, but still recommends the shot for use against the corona virus.

In this case, the patient, who lives in the western province of Alberta and received a version of the AstraZeneca vaccine supplied by the Serum Institute of India, “has received treatment and is recovering,” Canadian health authorities wrote on Twitter. Canada reported its first case of blood clotting associated with low platelets on Tuesday in a Quebec woman who received the same shot.

The authorities insist blood clot formations linked to the AstraZeneca vaccine “remain very rare” and Canada still believes that the vaccine’s benefits “outweigh the potential risks,” Health Canada and the Public Health Agency of Canada said.

At the end of March Canada’s National Advisory Committee on Immunization recommended suspending the use of the AstraZeneca vaccine in people under the age of 55 while it evaluated the risks. However Health Canada said that according to its analysis, limiting the use of the vaccine to certain populations was not necessary for the moment.

Canada’s vaccine campaign is now gaining momentum with 23.3 percent of the Canadian population having received at least one vaccine dose according to the Covid-19 Tracker Canada website. The country is facing a third coronavirus wave, however, that has recently forced provinces to tighten restrictions. Ontario, which has the highest number of cases, announced Friday it would strengthen and extend lock down measures until May 19, and also close its borders with the provinces of Quebec and Manitoba.

Canada has recorded more than 1.1 million cases of Covid-19 since the start of the pandemic and more than 23,500 deaths.

Stay tuned to BaaghiTV for latest news and Updates!


Leave A Reply

Your email address will not be published.